Systemic lidocaine in pain due to peripheral nerve injury and predictors of response
- PMID: 14745057
- DOI: 10.1212/01.wnl.0000103237.62009.77
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response
Abstract
Objective: To investigate the effects of IV lidocaine on spontaneous and evoked pain (allodynia and hyperalgesia) due to peripheral nerve injury (postherpetic neuralgia or nerve trauma) using quantitative sensory testing.
Method: The authors randomized 22 patients to receive lidocaine 5 mg/kg IV during 30 minutes or placebo in a double-blind crossover design and 16 patients subsequently received mexiletine on an open basis titrated from 400 to 1,000 mg per day (mean 737 mg/day).
Results: Lidocaine induced a significant decrease in ongoing pain for up to 6 hours with a peak effect 60 to 120 minutes postinjection. The drug also decreased mechanical dynamic allodynia and static (punctate) mechanical allodynia/hyperalgesia, but not thermal allodynia and hyperalgesia. The effects of lidocaine and mexiletine on spontaneous pain intensity were significantly higher in patients with concomitant mechanical allodynia in comparison with those without allodynia.
Conclusions: These data indicate modality-specific antihyperalgesic effects of IV lidocaine in patients with peripheral nerve injury. Patients with mechanical allodynia may be good candidates for treatment with local anesthetic-like drugs and possibly with other sodium-channel blockers.
Similar articles
-
Intravenous lidocaine for neuropathic pain: diagnostic utility and therapeutic efficacy.Curr Pain Headache Rep. 2007 Feb;11(1):20-4. doi: 10.1007/s11916-007-0017-7. Curr Pain Headache Rep. 2007. PMID: 17214917 Review.
-
The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study.Anesth Analg. 2009 Apr;108(4):1311-9. doi: 10.1213/ane.0b013e318198317b. Anesth Analg. 2009. PMID: 19299805 Clinical Trial.
-
Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain.Pain. 2001 Mar;91(1-2):177-87. doi: 10.1016/s0304-3959(00)00433-4. Pain. 2001. PMID: 11240090 Clinical Trial.
-
The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain.Acta Anaesthesiol Scand. 2003 Aug;47(7):868-77. doi: 10.1034/j.1399-6576.2003.00187.x. Acta Anaesthesiol Scand. 2003. PMID: 12859309 Clinical Trial.
-
Systemic lidocaine for neuropathic pain relief.Pain. 2000 Jul;87(1):7-17. doi: 10.1016/S0304-3959(00)00229-3. Pain. 2000. PMID: 10863041 Review.
Cited by
-
Sodium channel blockers for the treatment of neuropathic pain.Neurotherapeutics. 2009 Oct;6(4):663-78. doi: 10.1016/j.nurt.2009.08.001. Neurotherapeutics. 2009. PMID: 19789071 Free PMC article. Review.
-
Antinociceptive effect of ambroxol in rats with neuropathic spinal cord injury pain.Pharmacol Biochem Behav. 2010 Dec;97(2):249-55. doi: 10.1016/j.pbb.2010.08.006. Epub 2010 Aug 21. Pharmacol Biochem Behav. 2010. PMID: 20732348 Free PMC article.
-
The Potential Role of Sensory Testing, Skin Biopsy, and Functional Brain Imaging as Biomarkers in Chronic Pain Clinical Trials: IMMPACT Considerations.J Pain. 2017 Jul;18(7):757-777. doi: 10.1016/j.jpain.2017.02.429. Epub 2017 Feb 27. J Pain. 2017. PMID: 28254585 Free PMC article. Review.
-
Stratifying patients with peripheral neuropathic pain based on sensory profiles: algorithm and sample size recommendations.Pain. 2017 Aug;158(8):1446-1455. doi: 10.1097/j.pain.0000000000000935. Pain. 2017. PMID: 28595241 Free PMC article.
-
Intravenous lidocaine for neuropathic pain: diagnostic utility and therapeutic efficacy.Curr Pain Headache Rep. 2007 Feb;11(1):20-4. doi: 10.1007/s11916-007-0017-7. Curr Pain Headache Rep. 2007. PMID: 17214917 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical